EUVIMEDEUVIMED entdecken
Open Access

Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation

Oren Pasvolsky, Sarah Pasyar, Roland L Bassett iD, Hina N Khan, Mark R Tanner, Qaiser Bashir, Samer Srour iD, Neeraj Saini, Paul Lin, Jeremy Ramdial iD, Yago Nieto iD, Hans C Lee und 8 weitere

Cancer · 2024

DOI: 10.1002/cncr.35171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Oren Pasvolsky und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic significance of minimal residual disease (MRD) status before autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple myeloma (MM) has not been clearly elucidated.

Methods

Retrospective single‐center study of adult MM patients who achieved ≥very good partial response (VGPR) after induction therapy from 2015 to 2021 received upfront autoHCT and had available pretransplant MRD status by next‐generation flow cytometry. The cohort was divided into pretransplant MRD‐negative (MRDneg) and MRD‐positive (MRDpos) groups.

Results

A total of 733 patients were included in our analysis; 425 were MRDneg and 308 MRDpos at autoHCT. In the MRDpos group, more patients had high‐risk cytogenetic abnormalities (48% vs. 38%, respectively; p = .025), whereas fewer patients achieved ≥CR before autoHCT (14% vs. 40%; p < .001). At day 100 after autoHCT, 37% of the MRDpos versus 71% of the MRDneg achieved ≥CR, and at best posttransplant response 65% versus 88% achieved ≥CR, respectively. After a median follow‐up of 27.6 months (range, 0.7–82.3), the median PFS was significantly shorter for patients in the MRDpos group compared to the MRDneg group: 48.2 months (95% confidence interval [CI], 0.3–80.5) versus 80.1 months (95% CI, 0.5–80.1), respectively ( p < .001). There was no significant difference in overall survival between the two groups ( p = .41). Pretransplant MRDpos status was predictive of shorter PFS in multivariate analysis (hazard ratio, 1.80; 95% CI, 1.31–2.46; p < .001). The impact of pretransplant MRD status was retained in most of the examined subgroups.

Conclusions

In patients achieving ≥VGPR to induction, pretransplant MRDpos status was associated with a lower CR rate after autoHCT and a shorter PFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationAdultHumansTreatment OutcomeNeoplasm, ResidualRetrospective StudiesTransplantation, Autologous

Stichwörter der Autor:innen

autologousminimal residual diseasemultiple myelomatransplantation

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematology/Oncology, McGovern Medical School, The University of Texas Health Sciences Center at Houston, Houston, Texas, USA.

ORCID-Profile: Roland L Bassett, Samer Srour, Jeremy Ramdial, Yago Nieto, Muzaffar H Qazilbash

Förderung

  • NCI NIH HHS

Zitieren

APA

Pasvolsky, O., Pasyar, S., Bassett, R. L., Khan, H. N., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Ramdial, J., Nieto, Y., Lee, H. C., Patel, K. K., Kebriaei, P., Thomas, S. K., Weber, D. M., Orlowski, R. Z., Shpall, E. J., Champlin, R. E., & Qazilbash, M. H. (2024). Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. https://doi.org/10.1002/cncr.35171

Vancouver

Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, et al. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024. doi:10.1002/cncr.35171

BibTeX
@article{Pasvolsky2024,
  author = {Pasvolsky, Oren and Pasyar, Sarah and Bassett, Roland L and Khan, Hina N and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Ramdial, Jeremy and Nieto, Yago and Lee, Hans C and Patel, Krina K and Kebriaei, Partow and Thomas, Sheeba K and Weber, Donna M and Orlowski, Robert Z and Shpall, Elizabeth J and Champlin, Richard E and Qazilbash, Muzaffar H},
  title = {Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35171}
}
Kostenlos starten →